Literature DB >> 2058460

Atherogenicity of autoantibodies against low density lipoprotein.

A N Orekhov1, V V Tertov.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 2058460     DOI: 10.1007/bf01983338

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


× No keyword cloud information.
  4 in total

1.  Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination.

Authors:  A N Orekhov; V V Tertov; S N Pokrovsky; O N Martsenyuk; A A Lyakishev; V N Smirnov
Journal:  Circ Res       Date:  1988-03       Impact factor: 17.367

2.  Correlation between cholesterol content in circulating immune complexes and atherogenic properties of CHD patients' serum manifested in cell culture.

Authors:  V V Tertov; A N Orekhov; K S Sayadyan; S G Serebrennikov; A G Kacharava; A A Lyakishev; V N Smirnov
Journal:  Atherosclerosis       Date:  1990-04       Impact factor: 5.162

3.  Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells.

Authors:  A N Orekhov; V V Tertov; S A Kudryashov; V N Smirnov
Journal:  Circ Res       Date:  1990-02       Impact factor: 17.367

4.  Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients.

Authors:  A N Orekhov; V V Tertov; D N Mukhin; I A Mikhailenko
Journal:  Biochem Biophys Res Commun       Date:  1989-07-14       Impact factor: 3.575

  4 in total
  1 in total

Review 1.  Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value.

Authors:  Igor A Sobenin; Jukka T Salonen; Andrey V Zhelankin; Alexandra A Melnichenko; Jari Kaikkonen; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Biomed Res Int       Date:  2014-06-18       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.